RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album
El-Elimat, T., Raja, HA., Figueroa, M., Swanson, SM., Falkinham III, JO., Lucas, DM., Grever, MR., Wani, M., Pearce, CJ., & Oberlies, NH. (2015). Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album. Journal of Antibiotics, 68(3), 191-196. https://doi.org/10.1038/ja.2014.125
As part of an ongoing project to explore filamentous fungi for anticancer and antibiotic leads, 11 compounds were isolated and identified from an organic extract of the fungus Scytalidium album (MSX51631) using bioactivity-directed fractionation against human cancer cell lines. Of these, eight compounds were a series of sorbicillinoid analogs (1-8), of which four were new (scalbucillin A (2), scalbucillin B (3), scalbucillin C (6) and scalbucillin D (8)), two were phthalides (9-10) and one was naphthalenone (11). Compounds (1-11) were tested in the MDA-MB-435 (melanoma) and SW-620 (colon) cancer cell lines. Compound 1 was the most potent with IC50 values of 1.5 and 0.5 muM, followed by compound 5 with IC50 values of 2.3 and 2.5 muM at 72 h. Compound 1 showed a 48-h IC50 value of 3.1 muM when tested against the lymphocytic leukemia cell line OSU-CLL, while the nearly identical compound 5 had almost no activity in this assay. Compounds 1 and 5 showed selective and equipotent activity against Aspergillus niger with minimum IC values of 0.05 and 0.04 mug ml-1 (0.20 and 0.16 muM), respectively. The in vitro hemolytic activity against sheep erythrocytes of compounds 1 and 5 was investigated and were found to provoke 10% hemolysis at 52.5 and 45.0 mug ml-1, respectively, indicative of a promising safety factor.The Journal of Antibiotics advance online publication, 24 September 2014; doi:10.1038/ja.2014.125